My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 505

    1.

    The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.

    Werner C, Kamani CH, Gensch C, Böhm M, Laufs U.

    Diabetes. 2007 Oct;56(10):2609-15. Epub 2007 Jul 10.PMID: 17623816 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.

    Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, Wang SY, Hung A, Cherng WJ.

    Am Heart J. 2006 Dec;152(6):1051.e1-8.PMID: 17161050 [PubMed - indexed for MEDLINE]Related articles

    3.

    Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

    Sorrentino SA, Bahlmann FH, Besler C, Müller M, Schulz S, Kirchhoff N, Doerries C, Horváth T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U.

    Circulation. 2007 Jul 10;116(2):163-73. Epub 2007 Jun 25.PMID: 17592079 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta1.

    Redondo S, Hristov M, Gümbel D, Tejerina T, Weber C.

    Thromb Haemost. 2007 Jun;97(6):979-87.PMID: 17549301 [PubMed - indexed for MEDLINE]Related articles

    5.

    The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells.

    Gensch C, Clever YP, Werner C, Hanhoun M, Böhm M, Laufs U.

    Atherosclerosis. 2007 May;192(1):67-74. Epub 2006 Jul 28.PMID: 16876172 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

    Sourij H, Zweiker R, Wascher TC.

    Diabetes Care. 2006 May;29(5):1039-45.PMID: 16644634 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

    Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.PMID: 17520238 [PubMed - indexed for MEDLINE]Related articles

    8.

    Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.

    Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA.

    Diabetologia. 2009 Apr;52(4):723-32. Epub 2009 Jan 24.PMID: 19169664 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.

    Barac A, Campia U, Matuskey LA, Lu L, Panza JA.

    Am J Cardiol. 2008 Apr 1;101(7):980-5.PMID: 18359318 [PubMed - indexed for MEDLINE]Related articles

    10.

    Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

    Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

    J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.PMID: 16306801 [PubMed - indexed for MEDLINE]Related articles

    11.

    Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.

    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.

    Metabolism. 2007 Oct;56(10):1396-401.PMID: 17884451 [PubMed - indexed for MEDLINE]Related articles

    12.

    The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

    Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J.

    J Am Coll Cardiol. 2008 Sep 2;52(10):869-81. Epub 2008 Jul 2.PMID: 18755353 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.

    McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF.

    Diabetes Care. 2005 May;28(5):1145-50.PMID: 15855580 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.

    Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS, Jørgensen JO.

    Clin Endocrinol (Oxf). 2008 Sep;69(3):452-61. Epub 2008 Mar 10.PMID: 18331610 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

    Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M.

    Lancet. 2009 Jul 11;374(9684):126-35. Epub 2009 Jun 8.PMID: 19515415 [PubMed - indexed for MEDLINE]Related articles

    16.

    Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.

    Campia U, Matuskey LA, Panza JA.

    Circulation. 2006 Feb 14;113(6):867-75. Epub 2006 Feb 6.PMID: 16461819 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

    Zhao W, Thacker SG, Hodgin JB, Zhang H, Wang JH, Park JL, Randolph A, Somers EC, Pennathur S, Kretzler M, Brosius FC 3rd, Kaplan MJ.

    J Immunol. 2009 Aug 15;183(4):2729-40. Epub 2009 Jul 20.PMID: 19620300 [PubMed - indexed for MEDLINE]Related articles

    18.

    Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.

    Diabetes Care. 2006 May;29(5):1016-23.PMID: 16644631 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.

    Karagiannis E, Pfützner A, Forst T, Lübben G, Roth W, Grabellus M, Flannery M, Schöndorf T.

    Diabetes Technol Ther. 2008 Jun;10(3):206-12.PMID: 18473695 [PubMed - indexed for MEDLINE]Related articles

    20.

    PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells.

    Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P.

    Atherosclerosis. 2005 Nov;183(1):163-7.PMID: 15907852 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity